MARKET

AXGN

AXGN

Axogen Inc
NASDAQ
11.02
+0.28
+2.61%
Closed 16:30 09/26 EDT
OPEN
10.53
PREV CLOSE
10.74
HIGH
11.15
LOW
10.53
VOLUME
395.59K
TURNOVER
--
52 WEEK HIGH
16.75
52 WEEK LOW
6.87
MARKET CAP
465.97M
P/E (TTM)
-14.5363
1D
5D
1M
3M
1Y
5Y
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.
Benzinga · 09/12 07:23
Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet
The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upsi...
Zacks · 08/08 13:55
Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.
Zacks · 08/08 13:40
BRIEF-Axogen, Inc Reports Second Quarter Financial Results
BRIEF-Axogen, Inc Reports Second Quarter Financial Results
Reuters · 08/03 21:28
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 21:25
Axogen: Q2 Earnings Insights
Axogen (NASDAQ:AXGN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axogen beat estimated earnings by 60.0%, reporting an EPS of $-0.06 versus an estimate of $-...
Benzinga · 08/03 20:55
Axogen Q2 EPS $(0.06) Beats $(0.15) Estimate, Sales $34.50M Beat $33.85M Estimate
Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 33.33 percent increase over losses of $(0.09) per share from the same
Benzinga · 08/03 20:15
-- Earnings Flash (AXGN) AXOGEN Posts Q2 Loss $-0.06
-- Earnings Flash (AXGN) AXOGEN Posts Q2 Loss $-0.06
MT Newswires · 08/03 16:13
More
About AXGN
Axogen, Inc. is focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.

Webull offers kinds of AxoGen Inc stock information, including NASDAQ:AXGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGN stock methods without spending real money on the virtual paper trading platform.